The Medical Consensus on Product Differentiation

The path to common-sense regulation requires clear lines between natural botanicals and modified lab creations. At its annual meeting, the American Medical Association (AMA) updated its public health directives, focusing heavily on the exact priorities the Global Kratom Coalition and the Kratom Consumer Advisory Council (KCAC) have championed: restricting concentrated synthetic derivatives and protecting youth.

By targeting the actual drivers of public health risks rather than traditional botanical leaf, this update provides a vital framework for state and federal lawmakers.

Aligning on the Threat: Concentrated Synthetic 7-OH

The core of the updated policy centers on the proliferation of concentrated synthetic 7-hydroxymitragynine (7-OH). The AMA’s updated stance highlights exactly what our science-backed data has consistently shown, drawing a definitive line between the natural plant and lab-altered isolates.

As the AMA explicitly noted, 7-OH is a "potent opioid-like compound found naturally only in trace amounts in the kratom plant."

By identifying this distinction, the medical community supports our primary regulatory goals:

  • Distinct Risk Profiles: Highly concentrated synthetic 7-OH products are fundamentally different from natural leaf. The AMA warns that manufacturers are creating products that "can be significantly more potent than traditional kratom leaf" and that these synthetic isolates "may carry heightened risks of addiction, overdose, and other serious health harms."

  • Predatory Marketing & The Poison Center Narrative: We have long warned that the "kratom crisis" is actually a mislabeling crisis driven by synthetics. The AMA validates this, stating that concentrated synthetic 7-hydroxymitragynine 7-OH products are frequently "marketed in forms that appeal to young people, including flavored gummies, brightly colored packaging, and other candy-like presentations." Crucially, the AMA notes that these exact marketing practices have "coincided with increasing reports of pediatric exposures to poison centers."

  • Targeted Enforcement: The solution to these risks is strict and definitive. The AMA's newly adopted policy "calls for a ban on the sale, distribution, or marketing of [concentrated synthetic] 7-OH products and similar derivatives."

Moving Toward Evidence-Based Safeguards

To protect the public, the AMA is urging the U.S. Food and Drug Administration (FDA) and state legislatures to classify 7-OH products as "adulterated or misbranded when sold in child-friendly forms and prohibit their availability in retail stores and online platforms accessible to minors."

"While research continues, we cannot ignore the growing availability of unregulated products marketed in ways that appeal to children and adolescents. Concentrated [synthetic] 7-OH products are being sold in forms that can resemble candy and other treats, creating unnecessary risks for young people." — Dr. Melissa J. Garretson, AMA Board of Trustees

This targeted approach protects the public where the risk actually exists. It reinforces the AMA's recommendation that future regulations regarding the plant must be determined through "rigorous scientific research and clinical trials," focusing enforcement entirely on synthetic public health threats while preserving the integrity of the natural botanical supply chain.